Please assess the completion status of the following clinical trial:

Trial Title: DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have completed the Treatment Period of clinical trial DAR-311~* Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic~Exclusion Criteria:~* Subjects who discontinued treatment with study drug prior to the end of the Treatment Period of DAR-311 due to a study drug-related adverse event (AE)~* Treatment with another endothelin receptor antagonist within 6 months of study entry

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Darusentan 50 mg (Type: EXPERIMENTAL): Darusentan 50 mg administered orally once daily
- Darusentan 100 mg (Type: EXPERIMENTAL): Darusentan 100 mg administered orally once daily
- Darusentan 300 mg (Type: EXPERIMENTAL): Darusentan 300 mg administered orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).